2025 North America Cancer Vaccine Market Revenue Opportunities Report
Description
The 2025 North America Cancer Vaccine Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cancer Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the North America cancer vaccine market are Astellas Pharma, Merck, GlaxoSmithKline (GSK), and Bristol-Myers Squibb. These firms lead the market by leveraging advanced technologies such as mRNA and neo-antigen platforms to develop both therapeutic and prophylactic cancer vaccines. Merck, for instance, has invested heavily in mRNA personalization, exemplified by its partnership with Moderna for V940, while Bristol-Myers Squibb is pursuing bispecific combinations integrating vaccine priming with antibody-mediated cytotoxicity. GlaxoSmithKline focuses on combining traditional vaccine technologies with novel immunotherapies, and Astellas Pharma complements this landscape with its pipeline of candidates targeting various cancers.
These companies benefit from the increasing cancer incidence and screening rates in North America, which drive demand for vaccine-based interventions. Continued government and venture capital funding support vaccine R&D, while advanced healthcare infrastructure facilitates clinical trials and on-site personalized vaccine manufacturing at centers like Memorial Sloan Kettering. Moderna, though not always listed in the top four, plays a pivotal role with its mRNA-based cancer vaccines (e.g., mRNA-4157), showing promising clinical trial results. This focus on innovation positions these companies at the forefront of cancer vaccine development in North America, a market expected to grow significantly due to unmet medical needs and technological advancements.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cancer Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the North America cancer vaccine market are Astellas Pharma, Merck, GlaxoSmithKline (GSK), and Bristol-Myers Squibb. These firms lead the market by leveraging advanced technologies such as mRNA and neo-antigen platforms to develop both therapeutic and prophylactic cancer vaccines. Merck, for instance, has invested heavily in mRNA personalization, exemplified by its partnership with Moderna for V940, while Bristol-Myers Squibb is pursuing bispecific combinations integrating vaccine priming with antibody-mediated cytotoxicity. GlaxoSmithKline focuses on combining traditional vaccine technologies with novel immunotherapies, and Astellas Pharma complements this landscape with its pipeline of candidates targeting various cancers.
These companies benefit from the increasing cancer incidence and screening rates in North America, which drive demand for vaccine-based interventions. Continued government and venture capital funding support vaccine R&D, while advanced healthcare infrastructure facilitates clinical trials and on-site personalized vaccine manufacturing at centers like Memorial Sloan Kettering. Moderna, though not always listed in the top four, plays a pivotal role with its mRNA-based cancer vaccines (e.g., mRNA-4157), showing promising clinical trial results. This focus on innovation positions these companies at the forefront of cancer vaccine development in North America, a market expected to grow significantly due to unmet medical needs and technological advancements.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
